Sunday, 27 November 2022

4 September 2018

Over 50% of patients now enrolled!

We are delighted to bring you the news that successful randomisation of over 50% of NeoVanc’s target has been achieved. Congratulations to all the NeoVanc team on hitting this momentous milestone and for your on-going hard work and commitment to the trial. We look forward to continuing to work closely with you in achieving our target of 300 evaluable participants and we wish those sites still to recruit their first participant the best of luck!

Copyright © NeoVanc | All rights reserved. Read the disclaimer.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no: 602041
Privacy policy | Terms and conditions